Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639786 | 1.00 | ALDH1A1 (0.30) | — | |
| Lithium Ion SCHEMBL395589 | 0.86 | — | — | |
| SCHEMBL31511971 | 0.86 | ALDH1A1 (0.30) | — | |
| SCHEMBL1207561 | 0.86 | ALDH1A1 (0.30) | — | |
| Potassium Ion SCHEMBL640516 | 0.86 | ALDH1A1 (0.30) | — | |
| Lithium Ion SCHEMBL318795 | 0.86 | ALDH1A1 (0.30) | — | |
| SCHEMBL9641891 | 0.86 | ALDH1A1 (0.30) | — | |
| Potassium Ion SCHEMBL8433562 | 0.86 | — | — | |
| SCHEMBL9304336 | 0.86 | ALDH1A1 (0.30) | — | |
| Zinc Ion SCHEMBL917737 | 0.86 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110932-A | Method for synthesizing phthalide tetrahydroisoquinoline compound by tandem cyclization strategy | 沈阳药科大学 | 2020-12-22 | — | — | CN | claimed |
| US-5998614-A | Preparation of asymmetric cyclic ureas using an alkali metal in liquid ammonia process | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | claimed |
| US-20250266570-A1 | METHODS OF REACTIVE DRYING A SEPARATOR DURING BATTERY MANUFACTURING, DRIED SEPARATORS, AND BATTERIES CONTAINING THE SEPARATOR | Forge Nano, Inc. | 2025-08-21 | — | — | US | disclosed |
| WO-2023201094-A2 | METHODS OF REACTIVE DRYING A SEPARATOR DURING BATTERY MANUFACTURING, DRIED SEPARATORS, AND BATTERIES CONTAINING THE SEPARATOR | Forge Nano, Inc. (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-116444565-A | Silicon-containing biphosphine olefin compound, preparation method and application thereof | 铜陵欣诺科新材料有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022247920-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | 江苏恒瑞医药股份有限公司 | 2022-12-01 | — | — | WO | disclosed |
| EP-3356344-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022213980-A1 | TYK2 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-10-13 | — | — | WO | disclosed |
| CN-108473464-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| EP-1015467-A1 | 6,9-BRIDGED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5998614-A | Preparation of asymmetric cyclic ureas using an alkali metal in liquid ammonia process | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999012947-A1 | 6,9-BRIDGED ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-03-18 | — | — | WO | disclosed |
| EP-0831830-A4 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5780605-A | 6,9-bridged erythromycin derivatives | ABBOTT LABORATORIES (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |